H1 receptor x δ opioid receptor x κ opioid receptor x σ1 receptor x D2 receptor x Muscle-type nAChRs x μ opioid receptor x 5-HT2 receptor - 药物、适应症、专利

基本信息

关联

1

项与 H1 receptor x δ opioid receptor x κ opioid receptor x σ1 receptor x D2 receptor x Muscle-type nAChRs x μ opioid receptor x 5-HT2 receptor 相关的药物

Nicotine/Opipramol

尼古丁/奥匹哌醇

靶点

5-HT2 receptor x D2 receptor x H1 receptor x Muscle-type nAChRs x δ opioid receptor x κ opioid receptor x μ opioid receptor x σ1 receptor

作用机制

5-HT2 receptor拮抗剂 [+7]

在研机构-

原研机构

Mitsubishi Tanabe Pharma Corp.

在研适应症-

非在研适应症

注意缺陷障碍伴多动

最高研发阶段终止

首次获批国家/地区-

首次获批日期1800-01-20

1

项与 H1 receptor x δ opioid receptor x κ opioid receptor x σ1 receptor x D2 receptor x Muscle-type nAChRs x μ opioid receptor x 5-HT2 receptor 相关的临床试验

NCT01174355 / Completed临床1/2期

A Multicenter, Open Label, Escalating Dose Study to Assess the Tolerability and the Safety and to Explore the Efficacy and the Pharmacokinetics of ND0801 in Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)

A multicenter, open label, escalating dose study to assess the tolerability and the safety and to explore the efficacy and the pharmacokinetics of ND0801 in adult patients with attention deficit/hyperactivity disorder (ADHD).

开始日期2010-10-01

申办/合作机构

NeuroDerm Ltd.

100 项与 H1 receptor x δ opioid receptor x κ opioid receptor x σ1 receptor x D2 receptor x Muscle-type nAChRs x μ opioid receptor x 5-HT2 receptor 相关的临床结果

登录后查看更多信息

100 项与 H1 receptor x δ opioid receptor x κ opioid receptor x σ1 receptor x D2 receptor x Muscle-type nAChRs x μ opioid receptor x 5-HT2 receptor 相关的转化医学

登录后查看更多信息

0 项与 H1 receptor x δ opioid receptor x κ opioid receptor x σ1 receptor x D2 receptor x Muscle-type nAChRs x μ opioid receptor x 5-HT2 receptor 相关的专利（医药）

登录后查看更多信息

分析

对领域进行一次全面的分析。

登录

或

查看完整样例数据